WuXi Biologics passes FDA inspection

Hong Kong-listed WuXi Biologics said five Wuxi-based sites passed a nine-day FDA inspection with no critical findings, including three drug product plants and two drug substance facilities. The company added it has now secured 97 manufacturing licenses from regulators across six regions.